Verastem, Inc.

Verastem, Inc. is a development-stage biopharmaceutical company focused on discovering and developing drugs for cancer treatment in the United States. Its lead product candidates include Avutometinib, an orally administered small molecule dual RAF/MEK inhibitor designed to block MEK kinase activity and prevent compensatory reactivation of MEK by upstream RAF, targeting the RAS/MAPK signaling pathway commonly activated in various cancers. The company also develops Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for solid tumors. Verastem is conducting several clinical trials, such as RAMP 301, a global confirmatory trial evaluating the combination of Avutometinib and Defactinib for recurrent low-grade serous ovarian cancer, and RAMP 201, an adaptive trial for the same combination. Additionally, it has license agreements with Chugai Pharmaceutical for Avutometinib and with Pfizer for FAK inhibitors, and a clinical collaboration with Amgen to evaluate combination therapies.

Verastem, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol VSTM. The company's shares are traded in United States Dollars (USD), which is the official currency of the United States. As a US-based company listed on a US exchange, all financial reporting and trading activities are conducted in USD. Investors should be aware that currency fluctuations may affect the value of investments for those using other currencies.

Verastem, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies like Verastem use biological processes and living organisms to develop therapies, often focusing on innovative treatments for diseases such as cancer. As a development-stage biopharmaceutical company, Verastem is primarily engaged in research and clinical trials rather than commercial sales, which is typical for biotechnology firms working on novel drug candidates. The company's focus on oncology places it within the broader healthcare and life sciences field.

Verastem, Inc. is headquartered in the United States and primarily serves the US market. The company's description indicates it focuses on developing and commercializing drugs for cancer treatment in the United States. While it has international collaborations, such as license agreements with Chugai Pharmaceutical in Japan and Pfizer in the US, its core operations and target market are US-based. The company's clinical trials, including RAMP 301 and RAMP 201, are likely conducted in multiple countries, but its commercial strategy is centered on the US healthcare system.

As a development-stage biopharmaceutical company, Verastem does not currently have approved products generating revenue from sales. Its business model focuses on advancing its drug candidates through clinical trials to obtain regulatory approval. The company generates revenue primarily through license agreements and collaborations. For instance, it has a license agreement with Chugai Pharmaceutical for the development and commercialization of Avutometinib, and with Pfizer for FAK inhibitors. Additionally, Verastem has a clinical collaboration with Amgen to evaluate combination therapies. These partnerships may provide upfront payments, milestone payments, and royalties on future product sales. The company's portfolio includes several clinical programs, such as RAMP 301 for low-grade serous ovarian cancer and RAMP 205 for other indications, which, if successful, could lead to future revenue from product sales.